Table 3

Averaged antimicrobial resistance of the main Gram positive uropathogens for female and male patients
Antimicrobials group Antimicrobials S. aureus E. faecalis S. epidermidis
N % M F N % M F N % M F
Aminoglycosides Amikacin 1104 5.5 5.8 5.4 336 5.1 1.3 6.2
Gentamicin 1116 6.2 7.3 5.9 652 31.7 35.6 30.3 337 5.6 7.7 5.0
Isepamicin 1023 5.4 5.5 5.3 447 62.9 67.2 61.2 314 1.3 0.0 1.6
Netilmicin 1094 3.3 4.3 3.0 336 1.5 0.0 1.9
Tobramycin 1107 6.4 8.1 5.9 335 6.6 9.0 5.8
Carbapenems Imipenem 1106 2.1 3.9 1.5 672 6.3 5.2 6.7 336 0.0 0.0 0.0
Cephalosporins 1st G Cefazolin 1097 15.6 22.0 13.6 324 12.0 10.5 12.5
Cephradine 1083 16.5 24.1* 14.2 334 12.3 11.7 12.5
Cephalosporins 2nd G Cefoxitin 1097 16.6 20.2 15.5 337 13.1 9.1 14.2
Cefuroxime 1091 15.1 20.7 13.4 340 13.5 7.7 15.3
Cephalosporins 3rd G Cefodizime 841 10.8 12.8 10.2 245 8.2 6.8 8.6
Ceftazidime 1084 17.1 19.0 16.5 336 18.8 11.7 20.8
Ceftibuten 1088 11.1 14.9 10.0 339 13.6 7.8 15.3
Cephalosporins 4th G Cefepime 1086 10.7 14.2 9.6 338 11.8 9.1 12.6
Glycopeptides Teicoplanin 827 3.1 4.4 2.7 621 4.0 5.7 3.4 233 0.9 0.0 1.1
Vancomycin 777 2.6 3.6 2.2 472 1.1 0.0 1.4 218 0.0 0.0 0.0
Nitrofurans Nitrofurantoin 651 8.0 7.9 8.0
Penicillins AMX-CLA 1107 8.3 15.1* 6.3 665 9.5 9.6 9.4 338 3.0 1.3 3.5
Flucloxacillin 992 16.8 20.3 15.8 304 15.8 12.3 16.9
Penicillin 1036 55.1 64.5 52.2 646 59.8 61.6 59.1 315 58.1 45.9 61.8
Quinolones Ciprofloxacin 1103 18.0 33.3* 13.4 260 38.1 53.9* 31.5 331 26.6 32.9 24.8
Lomefloxacin 845 21.1 36.4* 15.8 206 45.1 58.9* 40.0 254 26.4 32.8 24.4
Norfloxacin 1073 18.3 32.9* 13.8 262 40.8 50.0 37.4 326 25.8 30.3 24.4
Ofloxacin 1091 17.8 31.9* 13.5 265 40.4 48.6 37.2 333 25.5 30.3 24.1
Sulfonamides SxT 1075 15.6 22.4* 13.5 609 35.5 45.3* 31.6 328 25.9 29.7 24.8

AMX - CLA Amoxicillin-clavulanic acid, SxT Trimethoprim-Sulfamethoxazole, n total number of bacteria resistant to each antimicrobial, N total number of bacteria tested against each antimicrobial; — Antimicrobial not tested, M male patient, F female patient, * statistically significant differences (p-value < 0.05) of antimicrobial resistance between female and male patients.

Linhares et al.

Linhares et al. BMC Infectious Diseases 2013 13:19   doi:10.1186/1471-2334-13-19

Open Data